Our data that targeting HELDR-activated KAT7 or targeting HELDR by ASOs augments anti-GBM activity by Erlotinib validated our observation that the previously uncharacterized HELDR-KAT7 axis promotes EGFR-driven GBM tumor malignancy independent of EGFR signaling. This evidence concerns the gene EGFR and neoplasm.